These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 2901077)

  • 21. A comparison of cinnarizine and transdermal scopolamine for the prevention of seasickness in naval crew: a double-blind, randomized, crossover study.
    Gil A; Nachum Z; Tal D; Shupak A
    Clin Neuropharmacol; 2012; 35(1):37-9. PubMed ID: 22139622
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Central anticholinergic syndrome in a pediatric patient following transdermal scopolamine patch placement.
    Holland MS
    Nurse Anesth; 1992 Sep; 3(3):121-4. PubMed ID: 1445954
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Transdermal scopolamine as a cause of transient psychosis in two elderly patients.
    Mego DM; Omori JM; Hanley JF
    South Med J; 1988 Mar; 81(3):394-5. PubMed ID: 3347867
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Transderm-induced psychosis in Parkinson's disease.
    Minagar A; Shulman LM; Weiner WJ
    Neurology; 1999 Jul; 53(2):433-4. PubMed ID: 10430448
    [No Abstract]   [Full Text] [Related]  

  • 25. Transderm-induced psychosis in Parkinson's disease.
    Quinn N
    Neurology; 2000 May; 54(9):1877. PubMed ID: 10802809
    [No Abstract]   [Full Text] [Related]  

  • 26. Toxic psychosis from transdermal scopolamine in a child.
    Sennhauser FH; Schwarz HP
    Lancet; 1986 Nov; 2(8514):1033. PubMed ID: 2877187
    [No Abstract]   [Full Text] [Related]  

  • 27. Transdermally administered scopolamine.
    Paasuke RT
    CMAJ; 1985 Nov; 133(10):956. PubMed ID: 4063911
    [No Abstract]   [Full Text] [Related]  

  • 28. Transdermal scopolamine use in the control of narcotic-induced nausea.
    Ferris FD; Kerr IG; Sone M; Marcuzzi M
    J Pain Symptom Manage; 1991 Aug; 6(6):389-93. PubMed ID: 1880439
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Delayed hypersensitivity to scopolamine delivered by a transdermal device.
    Trozak DJ
    J Am Acad Dermatol; 1985 Aug; 13(2 Pt 1):247-51. PubMed ID: 2931457
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Delirium due to scopolamine patch in a 4-year-old boy.
    Lin YG; Chen PH; Chang FY; Wu LT; Liao KY; Wu TC
    J Formos Med Assoc; 2011 Mar; 110(3):208-11. PubMed ID: 21497284
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Theory of antimotion sickness drug mechanisms.
    Wood CD; Graybiel A
    Aerosp Med; 1972 Mar; 43(3):249-52. PubMed ID: 4402925
    [No Abstract]   [Full Text] [Related]  

  • 32. Influence of transdermal scopolamine on motion sickness during 7 days' exposure to heavy seas.
    van Marion WF; Bongaerts MC; Christiaanse JC; Hofkamp HG; van Ouwerkerk W
    Clin Pharmacol Ther; 1985 Sep; 38(3):301-5. PubMed ID: 4028625
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Intranasal Scopolamine for Motion Sickness.
    Stankovic AS; Alvarenga DL; Coleman Daniels VR; Simmons RG; Buckey JC; Putcha L
    Aerosp Med Hum Perform; 2019 Nov; 90(11):917-924. PubMed ID: 31666152
    [No Abstract]   [Full Text] [Related]  

  • 34. Further experiments on the prevention of motion sickness.
    GLASER EM; HERVEY GR
    Lancet; 1952 Mar; 1(6706):490-2. PubMed ID: 14898786
    [No Abstract]   [Full Text] [Related]  

  • 35. Transdermal scopolamine: a review of its effects upon motion sickness, psychological performance, and physiological functioning.
    Parrott AC
    Aviat Space Environ Med; 1989 Jan; 60(1):1-9. PubMed ID: 2647072
    [TBL] [Abstract][Full Text] [Related]  

  • 36. I heard that the adhesive patch you can wear to prevent motion sickness is available again. Why was it taken off the market?
    Mayo Clin Health Lett; 1998 Mar; 16(3):8. PubMed ID: 9516375
    [No Abstract]   [Full Text] [Related]  

  • 37. Effect of transdermally administered scopolamine in preventing motion sickness.
    McCauley ME; Royal JW; Shaw JE; Schmitt LG
    Aviat Space Environ Med; 1979 Nov; 50(11):1108-11. PubMed ID: 393242
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Scopolamine for preventing and treating motion sickness.
    Spinks AB; Wasiak J; Villanueva EV; Bernath V
    Cochrane Database Syst Rev; 2004; (3):CD002851. PubMed ID: 15266468
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Toxic effect of scopolamine eye drops in children.
    Hamborg-Petersen B; Nielsen MM; Thordal C
    Acta Ophthalmol (Copenh); 1984 Jun; 62(3):485-8. PubMed ID: 6464693
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Control of simulator sickness in an AH-64 aviator.
    Kroll JD
    Aviat Space Environ Med; 1989 Dec; 60(12):1202-3. PubMed ID: 2604677
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.